|
Modified Simmons Catheter
Neurointerventions with improved success
Invention Summary:
The global neurovascular catheter market size was valued at USD 2.88 billion in 2020 and is expected to expand at a compound annual growth rate of 6.7% from 2021 to 2028. Neurointerventionalists, interventional radiologists, cardiologists, and vascular surgeons often can have...
Published: 8/25/2022
|
Inventor(s): Amit Singla
Keywords(s): Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Diagnostics, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Medical Devices
|
|
MicroRNA Based Therapeutics for Parkinson’s Disease
Protection of the mouse brain by microRNA-7 against the toxicity of a-synuclein (A) Tyrosine hydroxylase (TH) stained coronal section of mouse brain injected in the right striatum with AAV-miR-7 or non-targeting (NT) vector following by a-synuclein preformed fibrils (PFF) or PBS. (B) Substantia nigra sections. (C) Nigral dopamine neuron count. (D) Striatal...
Published: 8/23/2022
|
Inventor(s): M. Maral Mouradian, Eunsung Junn
Keywords(s): Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Biodegradable and Versatile Copolymers to Promote Wound Healing
Invention Summary:Rutgers scientists have developed a copolymer formulation to stably release salicylic acid (SA). It holds the promise for promoting topical and surgical wound healing, as SA is known to reduce local pain and inflammation as well as potentially prevent fibrous adhesion formation by reducing scar tissue. The release is stable over a...
Published: 12/8/2021
|
Inventor(s): Kathryn Uhrich, Sabrina Snyder
Keywords(s): Biomaterials, Drug Delivery, Neurological disorder & neuropathic pain, Wound healing
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Mobile Health Diagnostic for Schizophrenia
Invention Summary:
Schizophrenia is a psychiatric disorder characterized by hallucinations, disorganized thought, delusions, and a decline in both mental and physical functioning. The disorder affects about 1% of the population. Early detection and treatment significantly improves patient response to treatment; and can prevent progression to full...
Published: 12/8/2021
|
Inventor(s): Thomas Papathomas, Attila Farkas
Keywords(s): Mental Health, Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Software & Copyright, Technology Classifications > Medical Devices, Technology Classifications > Software & Algorithms, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Diagnostics
|
|
A Chemogenetic Therapy for Neuropathic Pain
Invention Summary:
Neuropathic pain (NP) typically arises as a consequence of a lesion or disease affecting peripheral nerve fibers. Prominent features in the pathophysiology of neuropathic pain include increased, ectopic neuronal activity in pain pathways. In general, NP is frequently refractory to conventional analgesics and currently there are...
Published: 12/8/2021
|
Inventor(s): Gary Aston-Jones
Keywords(s): Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics, Technology Classifications > Gene Therapy
|
|
Novel Gene Therapy to Treat L-DOPA-Induced Dyskinesia
Viral vector injections of rAAV-∆FosB shRNA significantly reduced abnormal involuntary movements (AIMs) compared to control vector in a rat model of Parkinson’s disease.Invention Summary:Parkinson's disease (PD) is a progressive, debilitating, and currently incurable neurodegenerative disease. Long-term dopamine replacement therapy in PD leads...
Published: 12/8/2021
|
Inventor(s): Mary Maral Mouradian, Stella Papa
Keywords(s): Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Gene Therapy, Technology Classifications > Therapeutics
|
|
Synergistic use of Coffee Components to Reduce Risk of Parkinson & other Neurodegenerative Diseases
Synergistic neuroprotection by two coffee components (EHT/Caffeine) to slow down progression of Parkinson’s Disease and Dementia with Lewy Bodies Invention Summary:Parkinson's disease (PD) is the second most common neurodegenerative disorder, and Dementia with Lewy bodies (DLB) is the second most common type of dementia after Alzheimer’s...
Published: 12/8/2021
|
Inventor(s): Mary Maral Mouradian, Jeffry Stock
Keywords(s): Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Food, Nutrition and Nutraceuticals
|
|
An Injectable and Long-Acting Local Anesthetics
Invention Summary: Local anesthetics prevent or relieve pain by interrupting nerve conduction. Even the long-acting local anesthetic agents (e.g., bupivacaine, levobupivacaine, ropivacaine) can only provide analgesia for 4-18 hours. Because of the short duration, local anesthetics often have to be given by repeated injection or continuous infusion....
Published: 12/8/2021
|
Inventor(s): Yuanxiang Tao, Xiaoyang Xu
Keywords(s): Neurological disorder & neuropathic pain, Surgery
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Sigma-1 Receptor Antagonists – Non-Addictive Pain Management
Invention Summary:
The sigma 1 receptor (S1R), a molecular chaperone protein located in the endoplasmic reticulum and plasma membranes, plays important roles in various pathological disorders including pain. The potential commercial applications of novel S1R antagonists are twofold: 1) as stand-alone therapy for the treatment of chronic neuropathic...
Published: 12/8/2021
|
Inventor(s): William Welsh, Youyi Peng
Keywords(s): Antiviral, Neurological disorder & neuropathic pain, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Treatment for Neuropsychiatric Disorders by Intravitreal Injection of DREADD Followed by Eye Drops or Pills Containing DREADD agonist
Figure 1. DREADD receptor-mediated activation of retinal cells prevents the development of light deprivation-induced depression-like behavior in vivo. A. DD-hM3Dq activation prevents the relative weight loss that was induced by constant dark lighting conditions. B. DREADD receptor-mediated activation of retinal cells leads to a reduction of depression-like...
Published: 12/8/2021
|
Inventor(s): Gary Aston-Jones, Hannah Bowrey
Keywords(s): Gene editing, Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
